首页> 中文期刊> 《中国继续医学教育》 >急性呼吸窘迫综合征合并肺动脉高压的治疗进展

急性呼吸窘迫综合征合并肺动脉高压的治疗进展

         

摘要

急性呼吸窘迫综合征合并肺动脉高压是临床危重症,呼吸支持治疗是急性呼吸窘迫综合征合并肺动脉高压的基础治疗方案,在呼吸支持治疗的基础上给予合理用药,控制过度全身性炎症反应,促进促炎/抗炎平衡的恢复,对治疗急性呼吸窘迫综合征合并肺动脉高压至关重要。急性呼吸窘迫综合征合并肺动脉高压的治疗药物包括NO吸入、钙离子增敏剂、前列腺素、HMG-CoA 还原酶抑制剂、磷酸二酯酶-5-抑制剂等。综合考虑多种病理机制,联合多种药物,或药物与非药物干预联合应用是目前较为公认的急性呼吸窘迫综合征合并肺动脉高压的治疗方向。%Acute respiratory distress syndrome complicated pulmonary hypertension is a clinical critically ill. Respiratory support therapy is the basis of the acute respiratory distress syndrome complicated pulmonary hypertension treatment. Respiratory support therapy on the basis of reasonable drug use. Control excessive systemic inflammatory response. Promote recovery of pro-inflammatory/anti-inflammatory balance. For the treatment of acute respiratory distress syndrome combined pulmonary hypertension is very important. The treatment of acute respiratory distress syndrome with pulmonary hypertension drugs including NO inhalation, calcium sensitization agent, prostaglandins, HMG Co-A reductase inhibitors, phosphodiesterase-5-inhibitor, phosphodiesterase inhibitors, etc. Considering a variety of pathological mechanism, combined a variety of drugs, or drug and non-drug intervention combined with application is now recognized as acute respiratory distress syndrome treated with pulmonary hypertension.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号